咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Prevalence of Cerebral Venous ... 收藏

Prevalence of Cerebral Venous Thrombosis in COVID-19 Patients: A Systematic Review

Prevalence of Cerebral Venous Thrombosis in COVID-19 Patients: A Systematic Review

作     者:Ohood A. Ashahrani Musa S. Alfaifi Ohood A. Ashahrani;Musa S. Alfaifi

作者机构:Department of Emergency Medicine Asir Central Hospital Abha KSA Department of Emergency Medicine Armed Force Hospital Southern Region Khamis Mushait KSA 

出 版 物:《Case Reports in Clinical Medicine》 (临床医学病理报告(英文))

年 卷 期:2022年第11卷第6期

页      面:207-217页

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:Prevalence CVT COVID-19 

摘      要:Background: COVID-19 is a novel coronavirus that has been rapidly transmitted between individuals globally. COVID-19 has been associated with thrombotic events. A cerebral venous thrombosis is a rare form of stroke with a most common site of origin believed to be the junction of larger sinuses and cerebral veins. So, it is important to identify the prevalence and incidence of cerebral venous thrombosis among COVID-19 patients. Aim: To assess the prevalence of cerebral venous thrombosis in COVID-19 patients by reviewing the previous studies reported on this subject. Method: We searched for articles focused on our subject through PubMed and Google scholar databases. The included searching terms included “CVT, COVID-19, Prevalence, Complications, and Effect. The inclusion criteria were studies conducted on COVID-19 patients, English articles, available full-text articles, and original articles. Result: We got 1178 articles;only six articles were eligible for the inclusion criteria. The included articles involved a total number of 551,727 participants with a mean age ranging between 34 years and 53.3 years and covered seven countries. The incidence of CVT among COVID-19 was reported as well as risk factors and symptoms. Conclusion: The incidence of CVT is high among COVID-19 patients compared to the general population, patients with influenza, and those who received the mRNA vaccine, whereas the prevalence requires further studies for precise data. A management strategy or treatment regimen should be established based on the severity of CVT patients, as the mortality rate among those patients was high.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分